IDI COGT 深 沪
已收盘 08-22 16:00:00 美东时间
12.12
+0.350
+2.97%
华盛通- 最 高12.44
- 今 开11.91
- 成交量 114.83万股
- 最 低 11.81
- 昨 收 11.77
- 总市值 13.82亿
- 52周最高 12.97
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.72
- 委 比 -36.34%
- 总股本 1.14亿
- 历史最高 27.80
- 量 比 1.15
- 振 幅 5.35%
- 历史最低 3.67
- 每 手 1
- 风险率 2.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CarParts.com Reports Second Quarter 2025 Results
TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle rep...
08-13 04:01
WOW! REPORTS SECOND QUARTER 2025 RESULTS
Greenfield markets now pass 91.1 thousand homes with a penetration rate at 16.0% ENGLEWOOD, Colo., Aug. 11, 2025 /PRNewswire/ -- WideOpenWest, Inc. ("WOW!" or the "Company") (NYSE: WOW), one...
08-12 04:54
AVALON HOLDINGS CORPORATION ANNOUNCES SECOND QUARTER RESULTS
WARREN, Ohio, Aug. 8, 2025 /PRNewswire/ -- Avalon Holdings Corporation (NYSE Amex: AWX) today announced financial results for the second quarter of 2025. Net operating revenues in the second...
08-09 05:05
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $30
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $29 to $30.
08-08 03:10
Century Casinos, Inc. Announces Second Quarter 2025 Results
Company Initiates Strategic Review Process to Enhance Shareholder Value. COLORADO SPRINGS, Colo., Aug. 7, 2025 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Na...
08-07 18:00
Analysts’ Top Healthcare Picks: Cogent Biosciences (COGT), Adaptive Biotechnologies (ADPT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-06 18:50
Cogent Biosciences Q2 EPS $(0.53) Beats $(0.58) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.58) by 9.4 percent. This is a 10.17 percent increase over losses of $(0.59) per share from
08-06 05:45
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Cogent Biosciences reported positive results from the SUMMIT trial for bezuclastinib in NonAdvanced Systemic Mastocytosis patients, achieving statistical significance across primary and key secondary endpoints. The company also announced financial results, securing $800 million in capital through debt financing and a public offering, positioning it to fund operations through 2027. Upcoming milestones include top-line results from PEAK and APEX tr...
08-05 12:00
